Metropolitan Life Insurance CO Cti Biopharma Corp Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.2 - $6.01 $827 - $1,183	-197 Reduced 3.49%	5,454 $22,000
Q4 2022 Jun 14, 2023	BUY	$4.45 - $6.17 $876 - $1,215	197 Added 3.61%	5,651 $34 Million
Q3 2022 Jun 14, 2023	BUY	$5.36 - $7.43 $1,055 - $1,463	197 Added 3.61%	5,651 $32.9 Million
Q2 2022 Jun 20, 2023	BUY	$3.55 - $6.27 $699 - $1,235	197 Added 3.61%	5,651 $33,000
Q2 2022 Aug 11, 2022	BUY	$3.55 - $6.27 $20,061 - $35,431	5,651 New	5,651 $34,000

Q3 2018 Nov 14, 2018	SELL	$1.72 - $5.24 $33,369 - $101,661	-19,401 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$3.81 - $5.26 $73,917 - $102,049	19,401 New	19,401 $0

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.